valproic acid has been researched along with lenalidomide in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Scott, BL | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Adès, L; Amé, S; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Braun, T; Chermat, F; Chevret, S; Cheze, S; Cluzeau, T; de Botton, S; Dimicoli-Salazar, S; Duployez, N; Fenaux, P; Guerci-Bresler, A; Laribi, K; Marolleau, JP; Nimubona, S; Park, S; Peterlin, P; Preudhomme, C; Quesnel, B; Recher, C; Stamatoullas, A; Thepot, S; Toma, A; Vey, N; Wattel, E; Wickenhauser, S; Zerazhi, H | 1 |
| Seymour, JF; Wei, AH | 1 |
3 review(s) available for valproic acid and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
2 trial(s) available for valproic acid and lenalidomide
| Article | Year |
|---|---|
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Thalidomide; Treatment Outcome; Valproic Acid | 2015 |
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Valproic Acid | 2022 |
3 other study(ies) available for valproic acid and lenalidomide
| Article | Year |
|---|---|
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat | 2009 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Valproic Acid | 2022 |